LSE Capital approves JV with LABLINK for Sindh project

LSE Capital Limited (LSECL) has received board approval to join LABLINK Enterprises in a joint venture for pre-qualifying and bidding on a project in Sindh, Mettis Global reported on November 05, 2026. The exchange notification confirms approval of the proposed arrangement, but does not identify the project or disclose its value, timetable or expected financial contribution from either participant.

LABLINK is a registered sole proprietorship that imports and supplies medical, healthcare and surgical goods and equipment. Its products come from multinational principals including NIPRO and Baxter, while LSE Capital’s participation is tied to the upcoming qualification and bid process rather than a confirmed project award. For investors, the disclosure adds a potential healthcare-related project to LSE Capital’s activities, although the available information does not establish whether the venture will secure the work or generate revenue.